Five Prime Therapeutics (FPRX) Tops Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FPRX Hot Sheet
Join SI Premium – FREE
Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($1.04), $0.27 better than the analyst estimate of ($1.31).
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
